Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03629236 · ClinicalTrials.gov registry record · NA

Study to Evaluate Safety and Efficacy of GrafixPL for the Treatment of Venous Leg Ulcers

A NA study of Venous Leg Ulcer, sponsored by Osiris Therapeutics.

Completed
Registry status
NA
Development phase
200
Enrollment target
2
Study locations

NCT03629236 is a NA study of Venous Leg Ulcer that has completed, run by Osiris Therapeutics. The registered enrollment target is 200 participants, below the 239-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (16% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03629236, a NA study of Venous Leg Ulcer, has completed, sponsored by Osiris Therapeutics.

COMPLETED
Registry status
NA
Development phase
200 participants
Enrollment target
2
Study locations

Study Summary

A Multicenter, Prospective, Randomized, Open-Label Study with a Crossover Extension Option to Evaluate the Safety and Efficacy of GrafixPL for the Treatment of Chronic VLUs

Conditions Studied

Interventions

  • OTHER Control
  • OTHER GrafixPL

Study Locations (2)

Florida

  • Integral Clinical Trial Solutions - Doral

Massachusetts

  • SSH - Weymouth

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2018-06-27
Est. Completion 2021-06-24
Phase NA

Sponsor

Osiris Therapeutics

7 total trials

What the Registry Record Tells You About NCT03629236

The ClinicalTrials.gov registry entry for NCT03629236 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (16% lower). The listed sponsor is Osiris Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Venous Leg Ulcer appearing as the primary indexed condition, and to 2 interventions - of which Control is the first listed.

NCT03629236 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03629236 about?

NCT03629236 is a clinical study titled "Study to Evaluate Safety and Efficacy of GrafixPL for the Treatment of Venous Leg Ulcers". A Multicenter, Prospective, Randomized, Open-Label Study with a Crossover Extension Option to Evaluate the Safety and Efficacy of GrafixPL for the Treatment of Chronic VLUs

What is the current status of trial NCT03629236?

This trial is currently completed. It is a NA study. The enrollment target is 200 participants. The study started on 2018-06-27. Estimated completion is 2021-06-24.

What conditions does trial NCT03629236 study?

This clinical trial studies the following conditions: Venous Leg Ulcer.

What interventions are being tested in trial NCT03629236?

The interventions under investigation include: Control (OTHER), GrafixPL (OTHER).

Who is sponsoring clinical trial NCT03629236?

This trial is sponsored by Osiris Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03629236 being conducted?

This trial has 2 study locations across Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Venous Leg Ulcer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.